Literature DB >> 21694803

Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection.

Mary Hickson1.   

Abstract

Diarrhoea, as a common side effect of antibiotics, increases treatment costs and length of stay in acute healthcare facilities. One potential strategy to prevent this side effect is the concurrent use of probiotic bacteria or yeast. This review discusses the evidence for the efficacy of probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection; the potential mechanisms by which probiotics may work; their safety; what future research is required; and recommendations for use in clinical practice.

Entities:  

Keywords:  Clostridium difficile; antibiotic-associated diarrhoea; hospitalized adults; probiotics

Year:  2011        PMID： 21694803      PMCID： PMC3105609          DOI： 10.1177/1756283X11399115

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN： 1756-283X            Impact factor:   4.409


  61 in total

1.  Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study.

Authors:  Susanne Mueller; Katiana Saunier; Christiana Hanisch; Elisabeth Norin; Livia Alm; Tore Midtvedt; Alberto Cresci; Stefania Silvi; Carla Orpianesi; Maria Cristina Verdenelli; Thomas Clavel; Corinna Koebnick; Hans-Joachim Franz Zunft; Joël Doré; Michael Blaut
Journal:  Appl Environ Microbiol       Date:  2006-02       Impact factor: 4.792

2.  Lactobacillus and bifidobacteria combinations: a strategy to reduce hospital-acquired Clostridium difficile diarrhea incidence and mortality.

Authors:  Terry Graul; Alisha M Cain; Kelly D Karpa
Journal:  Med Hypotheses       Date:  2009-04-08       Impact factor: 1.538

3.  Screening of probiotic activities of forty-seven strains of Lactobacillus spp. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans.

Authors:  C N Jacobsen; V Rosenfeldt Nielsen; A E Hayford; P L Møller; K F Michaelsen; A Paerregaard; B Sandström; M Tvede; M Jakobsen
Journal:  Appl Environ Microbiol       Date:  1999-11       Impact factor: 4.792

4.  A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. The Swedish C. difficile Study Group.

Authors:  O Karlström; B Fryklund; K Tullus; L G Burman
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

5.  Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation--a randomized, double-blind trial.

Authors:  Nada Rayes; Daniel Seehofer; Tom Theruvath; Reinhold A Schiller; Jan M Langrehr; Sven Jonas; Stig Bengmark; Peter Neuhaus
Journal:  Am J Transplant       Date:  2005-01       Impact factor: 8.086

6.  Effects of amoxicillin-clavulanate combination on the motility of the small intestine in human beings.

Authors:  F Caron; P Ducrotte; E Lerebours; R Colin; G Humbert; P Denis
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 7.  Mechanisms of action of probiotics: recent advances.

Authors:  S C Ng; A L Hart; M A Kamm; A J Stagg; S C Knight
Journal:  Inflamm Bowel Dis       Date:  2009-02       Impact factor: 5.325

8.  Risk factors for Clostridium difficile infection.

Authors:  G E Bignardi
Journal:  J Hosp Infect       Date:  1998-09       Impact factor: 3.926

9.  Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial.

Authors:  Marlene Wullt; Marie-Louise Johansson Hagslätt; Inga Odenholt
Journal:  Scand J Infect Dis       Date:  2003

10.  Does eating yogurt prevent antibiotic-associated diarrhoea? A placebo-controlled randomised controlled trial in general practice.

Authors:  Shaun Conway; Andrew Hart; Allan Clark; Ian Harvey
Journal:  Br J Gen Pract       Date:  2007-12       Impact factor: 5.386
View more
  27 in total

1.  Efficacious outcome employing fecal bacteriotherapy in severe Crohn's colitis complicated by refractory Clostridium difficile infection.

Authors:  C A Duplessis; D You; M Johnson; A Speziale
Journal:  Infection       Date:  2011-12-08       Impact factor: 3.553

Review 2.  A review of the pharmacobiotic regulation of gastrointestinal inflammation by probiotics, commensal bacteria and prebiotics.

Authors:  L Vitetta; D Briskey; E Hayes; C Shing; J Peake
Journal:  Inflammopharmacology       Date:  2012-03-18       Impact factor: 4.473

3.  Factors influencing the development of antibiotic associated diarrhea in ED patients discharged home: risk of administering IV antibiotics.

Authors:  John Patrick Haran; Gregory Hayward; Stephen Skinner; Chris Merritt; David C Hoaglin; Patricia L Hibberd; Shan Lu; Edward W Boyer
Journal:  Am J Emerg Med       Date:  2014-07-30       Impact factor: 2.469

4.  Saccharomyces boulardii fungemia caused by treatment with a probioticum.

Authors:  Julie Bjerre Thygesen; Henning Glerup; Britta Tarp
Journal:  BMJ Case Rep       Date:  2012-03-27

5.  Rifaximin Therapy for Patients With Metronidazole-Unresponsive Clostridium difficile Infection.

Authors:  Muhammad Waqas; Khadija Mohib; Aniqa Saleem; Mahak Lnu; Sabeen Arjumand; Hafiz Habib Ur Rehman Khalil; Rukhshanda Nosheen; Sharmeen Abbas; Kanza M Maqsood; Kiran Abbas
Journal:  Cureus       Date:  2022-04-14

6.  Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.

Authors:  Kasper Krogh Andersen; Nika M Strokappe; Anna Hultberg; Kai Truusalu; Imbi Smidt; Raik-Hiio Mikelsaar; Marika Mikelsaar; Theo Verrips; Lennart Hammarström; Harold Marcotte
Journal:  Infect Immun       Date:  2015-11-16       Impact factor: 3.441

Review 7.  A gastrointestinal anti-infectious biotherapeutic agent: the heat-treated Lactobacillus LB.

Authors:  Vanessa Liévin-Le Moal
Journal:  Therap Adv Gastroenterol       Date:  2016-01       Impact factor: 4.409

Review 8.  The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection.

Authors:  Xingmin Sun; Simon A Hirota
Journal:  Mol Immunol       Date:  2014-09-18       Impact factor: 4.407

9.  Probiotics for the treatment of Clostridium difficile associated disease.

Authors:  Leo R Fitzpatrick
Journal:  World J Gastrointest Pathophysiol       Date:  2013-08-15

10.  A multicentre randomised controlled trial evaluating lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea in older people admitted to hospital: the PLACIDE study protocol.

Authors:  Stephen J Allen; Kathie Wareham; Caroline Bradley; Wyn Harris; Anjan Dhar; Helga Brown; Alwyn Foden; Way Yee Cheung; Michael B Gravenor; Sue Plummer; Ceri J Phillips; Dietrich Mack
Journal:  BMC Infect Dis       Date:  2012-05-06       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.